Defence Therapeutics Inc. (DTCFF)
USD 0.62
(3.69%)
USD 0.62
(3.69%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 4.06 Million CAD | 106.55% |
| 2023 | 1.96 Million CAD | 77.61% |
| 2022 | 1.1 Million CAD | 805.66% |
| 2021 | 122.25 Thousand CAD | 152.85% |
| 2020 | 48.35 Thousand CAD | 516.8% |
| 2019 | 7839.00 CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q4 | 4.06 Million CAD | 24.39% |
| 2024 Q2 | 2.96 Million CAD | 46.07% |
| 2024 Q1 | 2.02 Million CAD | 3.2% |
| 2024 Q3 | 3.26 Million CAD | 10.16% |
| 2023 Q1 | 1.23 Million CAD | 11.33% |
| 2023 FY | 1.96 Million CAD | 77.61% |
| 2023 Q4 | 1.96 Million CAD | 8.17% |
| 2023 Q3 | 1.81 Million CAD | -28.66% |
| 2023 Q2 | 2.54 Million CAD | 106.73% |
| 2022 Q4 | 1.1 Million CAD | 254.73% |
| 2022 FY | 1.1 Million CAD | 805.66% |
| 2022 Q3 | 312.13 Thousand CAD | 9.88% |
| 2022 Q2 | 284.07 Thousand CAD | -10.4% |
| 2022 Q1 | 317.06 Thousand CAD | 159.34% |
| 2021 Q1 | 51.46 Thousand CAD | 6.44% |
| 2021 FY | 122.25 Thousand CAD | 152.85% |
| 2021 Q4 | 122.25 Thousand CAD | -22.09% |
| 2021 Q3 | 156.92 Thousand CAD | 107.58% |
| 2021 Q2 | 75.59 Thousand CAD | 46.89% |
| 2020 Q1 | - CAD | 0.0% |
| 2020 Q4 | 48.35 Thousand CAD | 0.0% |
| 2020 FY | 48.35 Thousand CAD | 516.8% |
| 2019 FY | 7839.00 CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ContraFect Corporation | 32.53 Million USD | 87.514% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 92.38% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 57.608% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -863.54% |
| SQZ Biotechnologies Company | 50.03 Million USD | 91.882% |
| Intellipharmaceutics International Inc. | 12 Million USD | 66.175% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 94.395% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 93.117% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -5.467% |
| Marizyme, Inc. | 26.67 Million USD | 84.773% |
| Genus plc | 485 Million USD | 99.162% |
| Pharming Group N.V. | 244.07 Million USD | 98.336% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -102.075% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -61.425% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -6.894% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -6.122% |
| IMV Inc. | 37.93 Million USD | 89.292% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 65.513% |
| ONE Bio Corp. | 27.49 Million USD | 85.227% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 94.753% |
| Neon Bloom, Inc. | 1.22 Million USD | -231.262% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 21.066% |
| Biomind Labs Inc. | 1.49 Million USD | -171.049% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 96.579% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 77.928% |
| Skye Bioscience, Inc. | 14.07 Million USD | 71.135% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -183.289% |
| Mesoblast Limited | 188.44 Million USD | 97.844% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -2758.633% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 57.088% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1919.717% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 29.306% |
| GB Sciences, Inc. | 5.41 Million USD | 25.022% |
| MultiCell Technologies, Inc. | 1617.67 USD | -251000.348% |
| Alpha Cognition Inc. | 7.16 Million USD | 43.306% |
| HST Global, Inc. | 593.59 Thousand USD | -584.303% |
| CSL Limited | 18.62 Billion USD | 99.978% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Agentix Corp. | 2.51 Million USD | -61.796% |
| Halberd Corporation | 728.71 Thousand USD | -457.413% |
| Enzolytics Inc. | 365.26 Million USD | 98.888% |
| Resverlogix Corp. | 67.39 Million USD | 93.973% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -384.3% |
| argenx SE | 444.95 Million USD | 99.087% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -136.988% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 95.102% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -10.827% |
| Bioxytran, Inc. | 3.24 Million USD | -25.003% |
| Zenith Capital Corp. | 27.56 Thousand USD | -14633.85% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -8.775% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -496.618% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -49.798% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.694% |
| Kadimastem Ltd | 3.5 Million USD | -15.895% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -5969.081% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 55.078% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 91.919% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 30.477% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -105.015% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 1.07 Million USD | -276.374% |
| EV Biologics, Inc. | 2.11 Million USD | -92.049% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -774.109% |
| Q BioMed Inc. | 8.13 Million USD | 50.055% |
| LadRx Corporation | 2.2 Million USD | -84.591% |
| Cell Source, Inc. | 15.8 Million USD | 74.302% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -8988.006% |
| Regen BioPharma, Inc. | 5.45 Million USD | 25.572% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 94.578% |
| Itoco Inc. | 1.65 Million USD | -145.711% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -97.994% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -222.586% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 83.585% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 32.849% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 65.875% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 3.99 Million USD | -1.708% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1602.035% |
| NovAccess Global Inc. | 7.86 Million USD | 48.326% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -9617.876% |
| BioStem Technologies, Inc. | 15.9 Million USD | 74.46% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -159.323% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -14706.893% |
| Qrons Inc. | 1.48 Million USD | -172.851% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 63.224% |
| SYBLEU INC | 681.41 Thousand USD | -496.111% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -402.226% |
| Rebus Holdings, Inc. | 5.24 Million USD | 22.511% |
| Regen BioPharma, Inc. | 5.45 Million USD | 25.572% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 33.431% |
| Affymax, Inc. | 8.87 Million USD | 54.211% |
| Mobile Lads Corp. | 1.31 Million USD | -209.249% |
| International Stem Cell Corporation | 5.27 Million USD | 23.025% |
| CytoDyn Inc. | 127.89 Million USD | 96.824% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -549.076% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 12.024% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 90.092% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 81.756% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -100.553% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 25.849% |
| Neutra Corp. | 973.52 Thousand USD | -317.242% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 86.0% |
| PureTech Health plc | 125.58 Million USD | 96.766% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -8.114% |
| IXICO plc | 1.9 Million USD | -113.755% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 80.213% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.069% |
| CSL Limited | 18.62 Billion USD | 99.978% |
| Cellectis S.A. | 249.36 Million USD | 98.371% |